Tag «Antineoplastic»

Foselutoclax

Foselutoclax CAS 2271269-01-1 MF C53H59ClF3N6O10PS3 MW 1159.7 g/mol (10R)-14-chloro-25-methyl-7,7-dioxo-10-[(phenylsulfanyl)methyl]-134-(phosphonooxy)-21-(propan-2-yl)-83-(trifluoromethanesulfonyl)-21H-7λ6-thia-6,9-diaza-4(1,4)-piperazina-13(1)-piperidina-2(2,3)-pyrrola-1(1),3(1,3),5,8(1,4)-tetrabenzenatridecaphane-24-carboxylic acid 5-(4-chlorophenyl)-2-methyl-4-[3-[4-[4-[[4-[[(2R)-1-phenylsulfanyl-4-(4-phosphonooxypiperidin-1-yl)butan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylamino]phenyl]piperazin-1-yl]phenyl]-1-propan-2-ylpyrrole-3-carboxylic acidB-cell lymphoma 2 (Bcl-2) inhibitor, antineoplastic, VT53CL5GES, UBX 1325 Foselutoclax is an investigational new drug that is being evaluated for the treatment of age-related eye diseases, particularly diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Developed by Unity Biotechnology, this senolytic compound acts as a potent inhibitor of Bcl-xL, a protein that senescent cells …

Fosdesdenosine sipalabenamide

Fosdesdenosine sipalabenamide CAS 2348493-39-8 MF C26H29N6O7P, MW=568.5 g/mol benzyl N-(P-ambo-3′-deoxy-OP-phenyl-5′-adenylyl)-Lalaninate benzyl (2S)-2-[[[(2S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate 3′-Deoxyadenosine 5′-O-phenyl-(benzoxy-L-alaninyl)-phosphatenucleoside analogue, antineoplastic, NUC 7738, Y7BFN2M72F Fosdesdenosine sipalabenamide is an investigational new drug that is being evaluated for the treatment of advanced solid tumors and lymphoma.[1] This compound is a phosphoramidate derivative of cordycepin (3′-deoxyadenosine), an adenosine analog originally isolated from the fungus Cordyceps.[2][3] As a nucleoside analog with potential antineoplastic properties, Fosdesdenosine sipalabenamide …

Flezurafenib

Flezurafenib CAS 2760321-00-2 MF C26H21FN4O3 MW456.5 g/mol, P26TTM6U27 5-({(3S)-3-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-3,4-dihydro-2H-1-benzopyran-6-yl}oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one 5-[[(3S)-3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]-3,4-dihydro-2H-chromen-6-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-onerapidly accelerated fibrosarcoma (Raf) kinase inhibitor,antineoplastic Flezurafenib is an investigational new drug designed as a rapidly accelerated fibrosarcoma (RAF) kinase inhibitor which is being evaluated for the treatment of cancer. Developed by Jazz Pharmaceuticals, this novel therapeutic agent is currently being explored for its efficacy against solid tumors and hematological malignancies harboring oncogenic mutations that …

Ezobresib

Ezobresib CAS 1800340-40-2 MF C30H33N5O2 MW 495.6 g/mol 2-{3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-olbromodomain and extra-terminal motif (BET) inhibitor,antineoplastic, BMS-986158, BMS 986158, Bristol Myers Squibb, antineoplastic, UNII-X8BW0MQ5PI 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Ezobresib is an investigational new drug that has been evaluated for the treatment of cancer. It inhibits Bromodomain and Extra-Terminal domain (BET) proteins, with potential antineoplastic activity.[1] Developed by Bristol Myers Squibb, this therapeutic agent has been studied for its efficacy in …

Epsametostat

Epsametostat CAS 2202678-06-4 MF C31H36F3N7O3 MW611.7 g/mol N-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-6-methyl-1-(6-methylpyridazin-3-yl)-5-{(1R)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethyl}indolizine-7-carboxamide N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-6-methyl-1-(6-methylpyridazin-3-yl)-5-[(1R)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethyl]indolizine-7-carboxamidehistone N-methyltransferase inhibitor, antineoplastic, Shanghai Haihe Pharmaceutical, HH 2853, (R)-HH2853 Epsametostat is an investigational new drug that is being evaluated for the treatment of peripheral T-cell lymphoma. It is a EZH1/EZH2 inhibitor developed by Shanghai Haihe Pharmaceutical Research & Development Co., Ltd.[1][2][3] PAT PAT https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018045971&_cid=P22-MGK809-27208-1 AS ON JUNE2025 4.45 LAKHS VIEWS ON BLOG WORLDREACH …

Enzomenib

Enzomenib CAS 2412555-70-3 MF C33H43FN6O3 MW 590.7 g/mol 5-fluoro-2-[4-[7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-N,N-di(propan-2-yl)benzamide 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,Ndi(propan-2-yl)benzamidemenin-MLL (mixed-lineage leukemia) protein, interaction inhibitor, antineoplastic, DSP-5336, Fast Track, Orphan Drug designations Enzomenib is an investigational new drug that is being evaluated for the treatment of acute leukemia.[1] It is a small molecule inhibitor that targets the interaction between menin and mixed-lineage leukemia (MLL) proteins.[2] Enzomenib particularly in patients with KMT2A (MLL) rearrangements or NPM1 mutations.[3] …

Dapolsertib

Dapolsertib CAS 1616359-00-2 MF C15H18Br2N4O MW 446.14 g/mol 5,6-dibromo-4-nitro-2-piperidin-4-yl-1-propan-2-ylbenzimidazole 5,6-dibromo-4-nitro-2-(piperidin-4-yl)-1-(propan-2-yl)-1H-1,3-benzimidazoleserine/ threonine kinase inhibitor, antineoplastic Ryvu Therapeutics SA, MEN1703, SEL24-B489 Dapolsertib is an investigational new drug that is being evaluated for the treatment of cancer. It is dual inhibitor of PIM family of serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3) that is being developed by Ryvu Therapeutics SA.[1] Dapolsertib …

Crelosidenib

Crelosidenib CAS 2230263-60-0 7-{[(1S)-1-(4-{(1S)-1-[4-(prop-2-enoyl)piperazin-1-yl]-2-cyclopropylethyl}phenyl)ethyl]amino}-1-ethyl-1,4-dihydro-2Hpyrimido[4,5-d][1,3]oxazin-2-oneisocitrate dehydrogenase 1 (IDH1) inhibitor, antineoplastic MF C28H36N6O3 MW 504.6 g/mol Crelosidenib is an investigational new drug that is being evaluated for the treatment of cancer. It acts as a selective inhibitor of isocitrate dehydrogenase 1 (IDH1), an enzyme that plays a crucial role in cellular metabolism and is frequently mutated in various cancers, including cholangiocarcinoma.[1][2] Crelosidenib is an …

Camibirstat

Camibirstat CAS 2671128-05-3 N-{(2S)-1-[(4-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl}-1,3-thiazol-2-yl)amino]-3-methoxy-1-oxopropan-2-yl}-1-(methanesulfonyl)-1H-pyrrole-3-carboxamideATPase inhibitor, antineoplastic MW C24H30N6O6S2 MF 562.7 g/mol Camibirstat is an investigational new drug that is being evaluated for the treatment of cancer. It is a small molecule that acts as a selective inhibitor of SMARCA2 and SMARCA4, which are key components of the SWI/SNF chromatin remodeling complex.[1] It is being developed by Foghorn Therapeutics.[2] Camibirstat is an orally bioavailable, allosteric, …

Brimarafenib

Brimarafenib CAS 1643326-82-2 MF C24H17F3N4O4 MW482.4 g/mol N-{(1S,1aS,6bS)-5-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl}-N′-(2,4,5-trifluorophenyl)urearapidly accelerated fibrosarcoma (Raf) kinase inhibitor, Antineoplastic, MapKure, LLC, SpringWorks Therapeutics, BeiGene, BGB-3245, BGB 3245, GXS33OY2CB Brimarafenib is an investigational new drug that is being evaluated for the treatment of cancer. It targets the proto-oncogene BRAF with activating mutations BRAF mutations (such as V600E), non-V600 BRAF mutations, and RAF fusions.[1][2] It is being developed by …